Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | QPCT | Q16769 | 13/20 | 0.51 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837784 | 0.85 | CYP19A1 (0.49) | CYP19A1QPCTQPCTLTLR9TLR7 | |
| SCHEMBL4839305 | 0.81 | CYP19A1 (0.45) | CYP19A1QPCTQPCTLTLR9TLR7 | |
| SCHEMBL5029097 | 0.77 | AGPAT2 (0.53) | GAA | |
| SCHEMBL5033308 | 0.77 | SOD1 (0.52) | QPCTALDH1A1SMN1; SMN2 | |
| SCHEMBL4836482 | 0.74 | GALR2 (0.53) | GAA | |
| SCHEMBL6863418 | 0.73 | CYP19A1 (0.41) | CYP19A1QPCTQPCTLTLR9TLR7 | |
| SCHEMBL4837017 | 0.73 | GALR1 (0.59) | CYP19A1 | |
| SCHEMBL6234629 | 0.72 | GALR1 (0.48) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4838923 | 0.71 | GALR1 (0.67) | SMN1; SMN2 | |
| SCHEMBL1473522 | 0.70 | IMPDH2 (0.73) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | CYP19A1 4658/4885QPCT 2110/4885QPCTL 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.